National Institute of Neurological Disorders and Stroke (NINDS)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Neurological Disorders and Stroke (NINDS) sits in the top decile of US sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count).
National Institute of Neurological Disorders and Stroke (NINDS): 567 sponsored US clinical trials, 48 recruiting.
National Institute of Neurological Disorders and Stroke (NINDS) sponsors 567 registered US clinical trials on ClinicalTrials.gov, 48 of them currently recruiting, and 467 completed. 16 of these trials are in Phase 3-4 (later-stage) and 158 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 23 trials.
Top-decile sponsor footprint
National Institute of Neurological Disorders and Stroke (NINDS) ranks in the top decile of sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
467 of 508 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
567 total, page 11 of 12
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
NCT00001785
Mexiletine for the Treatment of Focal Dystonia
NCT00001784
Motor Recovery in Recent Stroke Patients Treated With Amphetamine and Physical Therapy
NCT00001783
Areas of Brain Responsible for Understanding American Sign Language
NCT00001782
Magnetic Stimulation of the Human Nervous System
NCT00001780
Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)
NCT00001781
Timing of Levodopa Treatment in Parkinson's Disease
NCT00004733
Sertraline for the Treatment of Patients With Frontal Lobe Dementia (FLD)
NCT00001777
Vasodilation in Patients With Fabry's Disease
NCT00001774
Effects of Brain Stimulation on Learning and Reasoning
NCT00001776
The Classification and Cause of Leukodystrophies of Unknown Cause
NCT00001671
Language Localization Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Epilepsy
NCT00001672
Ketogenic Diet for Child Epilepsy and Seizure Control
NCT00004729
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
NCT00001669
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors
NCT00001668
Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy
NCT00001666
Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases
NCT00001667
Treatment of Cortical Myoclonus With Repetitive Transcranial Magnetic Stimulation
NCT00001663
Transcranial Magnetic Stimulation for the Treatment of Parkinson's Disease
NCT00001665
Sleep Disorders of Patients With Diseases of the Nervous System
NCT00001664
Mechanisms of Human Plasticity in the Human System
NCT00001661
Treatment of Alzheimer's Disease With CX516 (Ampalex)
NCT00001662
Vitamin Therapy for Prevention of Stroke
NCT00004734
Infrared Camera for Brain Mapping During Surgery
NCT00001554
Characteristics of Idiopathic Familial Speech Disorders
NCT00001551
Characteristics of Idiopathic Familial Voice Disorders
NCT00001552
Motor Changes Associated With Recovery From Stroke After Therapy
NCT00001553
Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)
NCT00001550
Diagnosis and Natural History Study of Patients With Neurological Conditions
NCT00001549
Analysis of the Nervous System in Patients With Fabry's Disease
NCT00001491
Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism
NCT00001489
PET Scan of Brain Metabolism in Relation to Age and Disease
NCT00001972
PET Scan in Patients With Neurocardiologic Disorders
NCT00001418
Direct Injection of Alcohol for the Treatment of Spinal Tumors
NCT00001417
Bone Response to Enzyme Replacement in Gaucher's Disease
NCT00001416
Potential Risk Factors for Stroke
NCT00001368
Diagnosis and History Study of Patients With Different Neurological Conditions
NCT00001367
Mapping the Areas of the Brain Associated With Language in Children With Epilepsy
NCT00001366
Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System
NCT00001365
Evaluation and Treatment of Patients Spinal Blood Vessel Abnormalities
NCT00001364
PET Scan to Map the Areas of the Brain Involved in Planning
NCT00001363
Magnetic Resonance Imaging for the Study of Patients With Neurological Disorders
NCT00001362
Magnetic Resonance Imaging Studies of Motor and Thought Processes
NCT00001361
Study of Norepinephrine Levels and Sympathetic Nervous System Activity
NCT00001329
Gene Therapy for the Treatment of Brain Tumors
NCT00001328
Establishing the Physiology of Syringomyelia
NCT00001327
Metabolic Abnormalities in Children With Epilepsy
NCT00001325
PET Scan to Study Brain Control of Human Movement
NCT00001324
Effects of Enzyme Replacement in Gaucher's Disease
NCT00001289
Brain Blood Flow Studies of Language and Memory
NCT00001288
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 80 |
| Phase 2 | 78 |
| Phase 3 | 11 |
| Phase 4 | 5 |
Therapeutic Areas
What is open in the National Institute of Neurological Disorders and Stroke (NINDS) pipeline
48 recruiting of 567 indexed (8% open); 467 completed (82%).
Phase mix: 16 late (III/IV) vs 158 early (I/II) (early-phase heavy).
Top condition: Healthy (23 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Neurological Disorders and Stroke (NINDS): open-pipeline peers nationwide
Peers matched on 567 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 567 trials (± recruiting share)
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
Sponsors near 8% open enrollment (± trial volume)
- National Jewish Health · 8% recruiting · 83 trials
- ACADIA Pharmaceuticals · 9% recruiting · 35 trials
- Texas Tech University Health Sciences Center, El Paso · 9% recruiting · 35 trials
- Boehringer Ingelheim · 8% recruiting · 515 trials
Related
What to do with this National Institute of Neurological Disorders and Stroke (NINDS) page
567 registered trials is a research-attention snapshot, not an endorsement of National Institute of Neurological Disorders and Stroke (NINDS) or any single study.
- 48 of National Institute of Neurological Disorders and Stroke (NINDS)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition National Institute of Neurological Disorders and Stroke (NINDS) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Neurological Disorders and Stroke (NINDS) pipeline card: 567 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.